Chronic pouchitis Program in Pharmaceutical Benefits Scheme (PBS) 012-24110514

This document outlines details of PBS-subsidised vedolizumab for patients with moderate to severe chronic pouchitis.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial or Recommencement after a break PB379 form	Written Electronic S100: vedolizumab i.v.	No	OPA	Must be treated by a: gastroenterologist consultant physician (internal medicine specialising in gastroenterology) consultant physician (general medicine specialising in gastroenterology)	Yes - immediate or delayed assessment (delayed if free text field used)
Continuing	Telephone Electronic S100: vedolizumab i.v.	No	OPA	Must be treated by a: gastroenterologist consultant physician (internal medicine specialising in gastroenterology) consultant physician (general medicine specialising in gastroenterology)	Yes
Balance of supply	Telephone Electronic S100: vedolizumab i.v.	No	OPA	Must be treated by a: gastroenterologist consultant physician (internal medicine specialising in gastroenterology) consultant physician (general medicine specialising in gastroenterology)	Yes

Delayed assessment due to free text used for antibiotics that are not on the list.

Table 2: this table lists the details of what to check for the delayed assessment applications.

Service Officers to assess that free text is:

Examples

Outcome

Relevant to the question category

Approve

Random text

Reject

Operational Information